The new subsidiary follows the recent announcement of Tetra's partnership with Cannvalate Pty Ltd for the performance of clinical trials of Tetra's drug candidates in Australia.
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
The second phase of the orientation workshop is being organized to provide in-depth knowledge to the state officials on core building blocks of ABDM
The Innopack confex is a perfect platform for exhibitors to demonstrate their latest developments in the fields of pharmaceutical packaging, labelling, drug delivery device design and engineering.
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
Susanne Kaestner joins the company as Senior Vice President, Quality and member of the Executive Team, and Dr. Thea Boehm as Vice President, Business Development.
Report lays out blueprint for achieving Organon’s purpose and business imperatives to help women and girls achieve their promise through better health
RH Capital, a leading women's health venture capital fund, announced three new investments to improve health outcomes for women in the US.
Subscribe To Our Newsletter & Stay Updated
